BioWorld

June 29, 2007

View Archived Issues

Serenex Raises $31M To Fund Mucositis And Hsp90 Programs

Serenex Inc. raised $31 million in Series D and debt funding to advance its lead compound for treating oral mucositis and the Hsp90 inhibitors behind that in the pipeline. (BioWorld Today) Read More

Series D Adds $20M To Propel Koronis' Viral Extinction Drug

Read More

Chromosome Transplant "Huge Enabling Step" For Artificial Life

Read More

CombinatoRx Drops CRx-150, Favors CRx-102 In Arthritis

Read More

Other News To Note

Read More

Clinic Roundup

Read More